The Parker Institute for Cancer Immunotherapy (PICI) collaborates with the Cancer Research Institute (CRI) on two key initiatives:

  • Tumor Neoantigen Selection Alliance (TESLA), through which CRI and PICI along with 30 of the world's leading cancer neoantigen research groups from academia and industry, aim to identify new molecular targets that may lead to next-generation, personalized immunotherapies. (Press release)
  • A multi-year clinical research collaboration with CRI and Bristol-Myers Squibb designed to accelerate immuno-oncology clinical studies across the CRI and PICI networks. (Press release)

Clinical trials co-funded and co-organized by PICI and CRI:

  • Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER) (NCT03835533)
  • Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer (AMADEUS) (NCT03651271)
  • Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (PRINCE) (NCT03214250)

Additional press releases: 

*Immunotherapy results may vary from patient to patient.